PCVX +16% on phase-2 data for VAX-24: https://finance.yahoo.com/news/vaxcyte-reports-positive-data-phase-103000816.html https://investors.vaxcyte.com/static-files/90fd9df6-3990-4954-acd8-8e24690783a0 VAX-24 is a 24-valent-pneumococcal vaccine. Please see #msg-170872992 and #msg-170868559 for background info.